Diseases Associated with Positive ANA Centromere Pattern
A positive ANA with centromere pattern is most strongly associated with limited cutaneous systemic sclerosis (lcSSc/CREST syndrome), followed by Raynaud's phenomenon and primary biliary cholangitis. 1
Primary Disease Associations
Systemic Sclerosis (Scleroderma)
- Limited cutaneous systemic sclerosis (lcSSc) is the predominant association, occurring in approximately 64% of ACA-positive patients 2
- The centromere pattern correlates with antigens CENP-A, CENP-B, and CENP-C directed against kinetochore proteins 1
- Patients typically present with CREST syndrome features: Calcinosis cutis, Raynaud's phenomenon, Esophageal dysfunction, Sclerodactyly, and Telangiectasia 3
- Prognostic significance: ACA positivity predicts a more benign course compared to diffuse cutaneous systemic sclerosis (dcSSc), with slower progression and less severe organ involvement 3, 2
- Raynaud's phenomenon often precedes scleroderma development by many years in ACA-positive patients 2
Primary Biliary Cholangitis (PBC)
- PBC occurs in approximately 8% of lcSSc cases, particularly in those with anti-centromere antibodies 4
- ACA is detected in 44-60% of ANA-positive PBC patients, with CENP-B ELISA being more sensitive than immunofluorescence for detection 5
- Clinical features include elevated alkaline phosphatase and generalized pruritus 4
- The presence of ACA in PBC may indicate concurrent autoimmune overlap syndromes 5
Raynaud's Phenomenon
- Isolated Raynaud's phenomenon represents approximately 12% of ACA-positive cases 2
- ACA screening should be conducted in all patients presenting with Raynaud's phenomenon, as it helps predict evolution to systemic sclerosis 3
- Patients with isolated Raynaud's and ACA positivity tend to be older at disease onset compared to those who develop lcSSc 2
Secondary Disease Associations
Sjögren's Syndrome
- Accounts for approximately 17% of ACA-positive patients 2
- ACA-positive Sjögren's patients demonstrate lower incidence of parotid gland enlargement and anti-La (SSB) antibodies compared to typical Sjögren's presentations 2
- Overlap with systemic sclerosis features is common 1
Other Autoimmune Diseases
- Rheumatoid arthritis: 3% of SSc cases overlap with RA; consider testing for rheumatoid factor and anti-CCP antibodies if inflammatory arthritis is present 4
- Systemic lupus erythematosus: Rare but documented; ACA can be detected in SLE patients with severe organ involvement including lupus nephritis and neuropsychiatric manifestations 6
- Inflammatory myositis, dermatomyositis, and polymyositis: Possible overlaps requiring investigation with extractable nuclear antibody profiles 4
Important Clinical Caveats
Screening Recommendations
- All ACA-positive patients require systematic organ screening including: 4
- Pulmonary function testing and high-resolution chest CT for interstitial lung disease
- Echocardiography and NT-proBNP for pulmonary arterial hypertension
- Regular blood pressure monitoring for scleroderma renal crisis (especially in dcSSc)
- Liver function tests for primary biliary cholangitis
Malignancy Considerations
- Anti-CENP-F antibodies (distinct from typical anti-centromere antibodies) are associated with increased malignancy risk, particularly in older patients with higher titers 7
- Anti-RNA polymerase III antibodies (not centromere pattern) carry higher malignancy risk in SSc 4
- Age-appropriate cancer screening should follow local guidelines 4
Pattern Recognition Pitfalls
- The centromere pattern shows 40 discrete fine nuclear punctuations attached to chromosomes during cell cycle phases on HEp-2 substrates 1, 8
- CENP-B ELISA may be more sensitive than immunofluorescence, identifying additional positive cases with indistinguishable ANA patterns 5
- Some patients may show mixed patterns (speckled appearance) requiring confirmatory testing with ELISA or Immunodot for CENP-A and CENP-B 8
Disease Evolution
- Most ACA-positive patients who meet autoimmune disease criteria at initial presentation maintain that diagnosis over time, with minimal interim diagnostic changes during long-term follow-up (mean 80 months) 9
- The initial clinical presentation typically determines the ultimate disease classification 9